Patents Assigned to Pfizer
  • Methods of treatment and formulations of cephalosporin
    Patent number: 7378408
    Abstract: Formulations containing an antibacterial alkali metal salt of a cephalosporin compound and methods of treating bacterial infections in dogs and cats.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: May 27, 2008
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Roger N. Kimball, Renuka D. Reddy, Evgenyi Y. Shalaev
  • SUBSTITUTED IMIDAZOLES
    Publication number: 20080119536
    Abstract: This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.
    Type: Application
    Filed: November 26, 2007
    Publication date: May 22, 2008
    Applicant: PFIZER LIMITED
    Inventors: NATHAN ANTHONY LOGAN CHUBB, MARK ROGER COX, JEROME SEBASTIEN DAUVERGNE, RICHARD ANDREW EWIN, CHRISTELLE LAURET
  • 2-amino-pyridine derivatives useful for the treatment of diseases
    Patent number: 7375100
    Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: May 20, 2008
    Assignee: Pfizer Inc
    Inventors: Alan Daniel Brown, Charlotte Alice Louise Lane, Russell Andrew Lewthwaite
  • HEAT TREATED BACTERINS, AND EMULSION VACCINES PREPARED FROM SUCH HEAT TREATED BACTERINS
    Publication number: 20080112970
    Abstract: Heat treated bacterins, a method of producing heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins are disclosed.
    Type: Application
    Filed: September 7, 2007
    Publication date: May 15, 2008
    Applicant: Pfizer Inc.
    Inventors: Mark D. Goodyear, Michael J. Huether, Ramasamy M. Mannan, Nancee L. Oien
  • Modified human IGF-IR antibodies
    Patent number: 7371378
    Abstract: The present invention relates to antibodies, which are directed to the human IGF-1 receptor (IGF-1R) and are to be administered for the treatment of cancer. The antibodies of the present invention have been altered to comprise antibodies with one or more selected germlne framework amino acid residues which replace one or more corresponding somatically mutated residues in the variable region of the unaltered antibody. The modification results in the framework region mutations converted to germline. The modification results in a reduced propensity for the antibody to elicit an immune response (reduced immunogenicity) following administration to a human subject.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: May 13, 2008
    Assignee: Pfizer Inc.
    Inventors: Bruce D. Cohen, Vahe Bedian
  • Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
    Patent number: 7371862
    Abstract: The present invention is directed to compounds of the formula or pharmaceutically acceptable salts, prodrug, solvate or optical isomer thereof, pharmaceutical compositions containing same and use thereof for treating diseases linked to disregulated cell proliferation or to disregulated protein kinase.
    Type: Grant
    Filed: November 11, 2005
    Date of Patent: May 13, 2008
    Assignee: Pfizer Italia S.r.l.
    Inventors: Ermes Vanotti, Francesco Angelucci, Alberto Bargiotti, Maria Gabriella Brasca, Antonella Ermoli, Maria Menichincheri
  • Triamide-substituted heterobicyclic compounds
    Patent number: 7368573
    Abstract: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: May 6, 2008
    Assignee: Pfizer Inc.
    Inventors: Peter Bertinato, Michel A. Couturier, Ernest S. Hamanaka, Marcus D. Ewing, Ralph P. Robinson, Derek L. Tickner
  • Tropane derivatives useful in therapy
    Patent number: 7368460
    Abstract: The present invention provides compounds of the formula: wherein R1 is C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C1-6 alkyl optionally substituted by one or more fluorine atoms, or C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: May 6, 2008
    Assignee: Pfizer, Inc.
    Inventors: Manoussos Perros, David Anthony Price, Blanda Luzia Christa Stammen, Anthony Wood
  • HIV-Integrase inhibitors, pharmaceutical compositions and methods for their use
    Patent number: 7368571
    Abstract: Bicycling hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: May 6, 2008
    Assignee: Pfizer Inc
    Inventors: Qiyue Hu, Atsuo Kuki, Dawn Marie Nowlin, Michael Bruno Plewe, Hai Wang, Junhu Zhang
  • BENZAZEPIN-2(1H)-ONE DERIVATIVES
    Publication number: 20080103130
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are agonists at the beta-2 adrenoceptor. They are useful as feed additives for livestock animals.
    Type: Application
    Filed: October 24, 2007
    Publication date: May 1, 2008
    Applicant: PFIZER LIMITED
    Inventors: Jessica Boyle, Ashley Fenwick, David Gethin, Catherine McCusker
  • Drugs And Prodrugs Useful The Treatment Of Energy Balance In Ruminants
    Publication number: 20080096916
    Abstract: The use of a compound of formula (I) an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug, in the manufacture of a medicament for the palliative, prophylactic or curative treatment of negative energy balance in ruminants. The use of a compound of formula 1, in the manufacture of a medicament for the palliative, prophylactic or curative treatment of ruminant disease associated with negative energy balance in ruminants, wherein, preferably, the ruminant disease associated with negative energy balance in ruminants is selected from fatty liver syndrome, dystocia, immune dysfunction, impaired immune function, toxification, primary ketosis, secondary ketosis, downer cow syndrome, indigestion, inappetence, retained placenta, displaced abomasum, mastitis, (endo-)-metritis, infertility, low fertility, and lameness.
    Type: Application
    Filed: November 9, 2005
    Publication date: April 24, 2008
    Applicant: PFIZER INC.
    Inventor: Marcus Kehrli
  • Lincomycin derivatives possessing antibacterial activity
    Patent number: 7361743
    Abstract: Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. The compounds of the subject invention may exhibit potent activities against bacteria, including Gram positive organisms, and may be useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.
    Type: Grant
    Filed: August 31, 2005
    Date of Patent: April 22, 2008
    Assignee: Pfizer Inc
    Inventors: Jason G. Lewis, Sampath K Anandan, Hardwin O'Dowd, Mikhail F Gordeev, Liansheng Li
  • Safe mutant viral vaccines
    Patent number: 7361357
    Abstract: The present invention provides safe vaccines and methods of preparing such vaccines. The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the two viruses or the encoding nucleic adds contains a mutation that confers a desirable phenotype and the mutations in the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: April 22, 2008
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Siao-Kun Wan Welch, Jay Gregory Calvert, Michael K. O'Hara, Xuemei Cao
  • Purified racemic lasofoxifene and purified lasofoxifene D-tartrate and a method for effective purification of racemic lasofoxifene
    Patent number: 7358374
    Abstract: A method for removing impurities from racemic cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol and purified cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol useful as an estrogen agonist/antagonist.
    Type: Grant
    Filed: March 28, 2005
    Date of Patent: April 15, 2008
    Assignee: Pfizer Inc.
    Inventors: Robert W. McLaughlin, Harry A. Watson, Jr., Constantine Sklavounos
  • Tetraazabenzo[e]azulene derivatives and analogs thereof
    Patent number: 7358242
    Abstract: This invention relates to CCK-A agonists of Formula (I) wherein R1-R4, A, B, X, D, E and G are as defined in the specification, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating diabetes.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: April 15, 2008
    Assignee: Pfizer Inc.
    Inventors: Richard L. Elliott, Kimberly O. Cameron, Marlys Hammond
  • Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes
    Patent number: 7354941
    Abstract: Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of Formula (1.0.0): wherein R5 and R6 are taken together to form a moiety of partial Formulas (1.1.1) through (1.1.5): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: April 8, 2008
    Assignee: Pfizer Products Inc.
    Inventors: Anthony Marfat, Robert James Chambers
  • Cannabinoid receptor ligands and uses thereof
    Patent number: 7354929
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: April 8, 2008
    Assignee: Pfizer Inc.
    Inventors: Philip A. Carpino, David A. Griffith
  • Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists
    Patent number: 7354925
    Abstract: This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a hydrogen atom, or the like; R4 represents a hydrogen atom or the like; represents one of the following or the like; R5 represents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxygen atom or the like and n represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: April 8, 2008
    Assignee: Pfizer Inc.
    Inventors: Yoshinobu Hashizume, Masako Hirota, Sachiko Mihara, Hisoshi Nakamura, Hiroki Koike, Yukari Matsumoto
  • Enzymatic resolution of selective estrogen receptor modulators
    Patent number: 7351567
    Abstract: The present invention relates to a process for preparing 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen-2-ol compounds useful as an estrogen agonist.
    Type: Grant
    Filed: March 2, 2004
    Date of Patent: April 1, 2008
    Assignee: Pfizer Inc.
    Inventor: Kevin K. Liu
  • Pyrimidine derivatives for the treatment of abnormal cell growth
    Patent number: 7351712
    Abstract: The present invention relates to a compound of the formula 1 wherein R1-R4 are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: April 1, 2008
    Assignee: Pfizer Inc
    Inventors: John Charles Kath, Michael Joseph Luzzio